通过网络医学和基于机制的分子内型重新解决痴呆症
Mayra Pacheco Pachado1, Ana I Casas1,2, Mahmoud H Elbatreek1,3
1Department of Pharmacology and Personalised Medicine, School of Mental Health and Neuroscience, Maastricht University, Maastricht, The Netherlands.
Journal of Alzheimer's disease : JAD
|September 24, 2023
概括
目前的痴呆症定义阻碍了阿尔茨海默病的药物开发. 网络医学提供了一个新的框架,从表型转向分子内型,用于精确的神经退行性疾病治疗.
科学领域:
- 神经退行性疾病 神经退行性疾病
- 精准医学是一门精准的医学.
- 网络医学 网络医学
背景情况:
- 阿尔茨海默病 (AD) 和痴呆症是老年人群中残疾和死亡的主要原因.
- 抗阿米洛伊德药物开发的失败率很高,抗阿米洛伊德干预措施的临床益处和潜在危害有限.
- 目前的疾病定义已经过时,专注于症状 (表型),而不是潜在的机制和并发症.
研究的目的:
- 确定当前痴呆症鼻科在推进精准医学方面的局限性.
- 提出网络医学作为克服这些局限性的解决方案.
- 为实现神经退行性疾病的精确和治愈性治疗引入一个新的框架.
主要方法:
- 对当前痴呆症鼻科学的以假设为导向的讨论.
- 阐明网络医学在重新定义疾病分类方面的潜力.
- 关于整合分子内型的新框架的建议.
主要成果:
- 确定过时的,基于表型的疾病定义是有效的阿尔茨海默病药物开发的主要障碍.
- 展示了网络医学如何促进从临床病理学表型向分子内型的转变.
- 在神经退行性疾病中提出了精准医学的新概念框架.
结论:
- 疾病定义的范式转变对于推进阿尔茨海默病和其他神经退行性疾病研究至关重要.
- 网络医学提供了一种强大的方法,可以根据分子机制重新定义疾病,为精确治疗铺平道路.
- 拟议的框架旨在为患有神经退行性疾病的患者提供治疗策略.
相关概念视频
Alzheimer's Disease: Overview
513
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
513
Dementia
131
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
131
Alzheimer's Disease: Treatment
212
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
212


